Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vistagen Therap. Com (VTGN)

Vistagen Therap. Com (VTGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,847
  • Shares Outstanding, K 143,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,770 K
  • 60-Month Beta 0.82
  • Price/Sales 195.26
  • Price/Cash Flow N/A
  • Price/Book 3.12
Trade VTGN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.99 +3.02%
on 03/30/21
2.43 -15.64%
on 03/22/21
-0.23 (-10.09%)
since 03/16/21
3-Month
1.83 +12.02%
on 02/10/21
3.18 -35.53%
on 02/22/21
-0.35 (-14.58%)
since 01/15/21
52-Week
0.35 +485.71%
on 05/14/20
3.18 -35.53%
on 02/22/21
+1.64 (+400.00%)
since 04/16/20

Most Recent Stories

More News
VistaGen's Poster Presentation at the Anxiety and Depression Association of America's 2021 Annual Conference Differentiates PH94B's Mechanism of Action from Highly-Addictive Benzodiazepines

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression...

VTGN : 2.05 (-2.84%)
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care...

VTGN : 2.05 (-2.84%)
VistaGen's PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of...

VTGN : 2.05 (-2.84%)
New Strong Sell Stocks for March 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

DGII : 18.34 (-1.98%)
PTN : 0.5392 (-7.03%)
IRT : 16.35 (+1.24%)
VTGN : 2.05 (-2.84%)
ISEE : 5.95 (-3.57%)
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS.

AVGR : 1.1400 (-5.79%)
CRVS : 2.71 (-2.52%)
RIGL : 3.58 (-5.29%)
BPTH : 5.58 (-5.26%)
VTGN : 2.05 (-2.84%)
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and -4.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

VTGN : 2.05 (-2.84%)
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021

Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD)...

VTGN : 2.05 (-2.84%)
VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression...

VTGN : 2.05 (-2.84%)
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression...

VTGN : 2.05 (-2.84%)
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ("VistaGen"), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety,...

VTGN : 2.05 (-2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 2.19
2nd Resistance Point 2.14
1st Resistance Point 2.10
Last Price 2.05
1st Support Level 2.00
2nd Support Level 1.95
3rd Support Level 1.91

See More

52-Week High 3.18
Fibonacci 61.8% 2.10
Last Price 2.05
Fibonacci 50% 1.76
Fibonacci 38.2% 1.43
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar